BioTuesdays
89bio
Markets

SVB Leerink starts 89bio at OP; PT $55

SVC Leerink initiated coverage of 89bio (NASDAQ:ETNB) with an “outperform” rating and $55 price target. The stock closed at $28.60 on Dec. 6. 89bio is developing a fibroblast growth factor (FGF) 21 analog, BIO89-100, in...

December 9, 2019
Diplomat Pharmacy
Markets

WB ups Diplomat Pharmacy to market perform

William Blair upgraded Diplomat Pharmacy (NYSE:DPLO) to “market perform” from “underperform” after UnitedHealth Group’s (NYSE:UNH) OptumRx agreed to acquire Diplomat for $4 a share. Shares of Diplomat were quoted at $3...

December 9, 2019
Puma Biotechnology Logo
Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019
ADMA Biologics Logo
Markets

Dawson James removes PT for ADMA Biologics

Dawson James Securities removed its prior $4 price target for ADMA Biologics (NASDAQ:ADMA) after the company reported third quarter financial results. The stock was changing hands at $4.09 in afternoon trading on Dec. 5...

December 5, 2019
Check Cap
Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019
Axsome Therapeutics
Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019
STAAR Surgical
Markets

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

December 4, 2019
TELA Bio
Markets

Piper Jaffray starts TELA Bio at OW; PT $17

Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...

December 3, 2019
BeyondSpring Logo
Markets

WB starts BeyondSpring at outperform

William Blair launched coverage of BeyondSpring (NASDAQ:BYSI) with an “outperform” rating. The stock closed at $12.45 on Dec. 2. According to analyst Andy Hsieh, the Street is “undervaluing the clinical potential” of...

December 3, 2019
Galera Therapeutics
Markets

BTIG starts Galera Therapeutics at buy; PT $30

BTIG launched coverage of Galera Therapeutics (NASDAQ:GRTX) with a “buy” rating and $30 price target. The stock closed at $12.53. Galera is focused on developing superoxide dismutase mimetics, first‐in‐class medicines...

December 2, 2019
Centogene Logo
Markets

SVB Leerink starts Centogene at OP; PT $21

SVB Leerink initiated coverage of Centogene NV (NASDAQ:CNTG) with an “outperform” rating and price target of $21.The stock closed at $12.97 on Nov. 29. “We see Centogene as a leader in rare disease diagnostics...

December 2, 2019
BioCardia
Markets

Brookline starts BioCardia at buy; PT $22

Brookline Capital Markets launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $22 price target. Near the close of trading on Nov. 27, the stock was quoted at $4.55. BioCardia is a developing CardiAMP...

November 29, 2019
Adamis Pharma
Markets

Dawson James cuts Adamis Pharma PT to $1 from $4

Dawson James reduced its price target for Adamis Pharmaceuticals (NASDAQ:ADMP) to $1 from $4 on the heels of an FDA complete response letter (CRL) for the company’s high-dose naloxone injection product for the treatment...

November 26, 2019
chemocentryx
Markets

SVB Leerink ups Chemocentryx PT to $50 from $27

SVB Leerink hiked its price target for Chemocentryx (NASDAQ:CCXI) to $50 from $27 after the company unveiled positive topline data from its Phase 3 ADVOCATE trial for avacopan. The stock closed at $8.06 on Nov. 25, but...

November 26, 2019
NextCure
Markets

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

November 26, 2019
CymaBay
Markets

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

November 25, 2019
Adamis Pharma
Markets

Maxim cuts Adamis Pharma to hold; withdraws PT

Maxim Group downgraded Adamis Pharmaceuticals (NASDAQ:ADMP) to “hold” from “buy” and withdrew its previous $3 price target after the company received a complete response letter (CRL) from the FDA regarding the NDA for...

November 25, 2019
VBL Therapeutics
Markets

Roth starts VBL Therapeutics at buy; PT $2.05

Roth Capital Partners initiated coverage of VBL Therapeutics (NASDAQ:VBLT) with a “buy” rating and price target of $2.05. The stock closed at $1.25 on Nov. 22. VBL Therapeutics is developing VB-111 for the treatment of...

November 25, 2019
Hepion Pharmaceuticals
Markets

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

November 22, 2019